Ingalls & Snyder LLC Decreases Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Ingalls & Snyder LLC cut its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 47.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,500 shares of the specialty pharmaceutical company’s stock after selling 10,188 shares during the period. Ingalls & Snyder LLC’s holdings in Supernus Pharmaceuticals were worth $359,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. HighTower Advisors LLC acquired a new stake in Supernus Pharmaceuticals in the third quarter valued at $264,000. PDT Partners LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 3rd quarter worth about $1,157,000. Martingale Asset Management L P lifted its stake in Supernus Pharmaceuticals by 4.6% during the third quarter. Martingale Asset Management L P now owns 37,796 shares of the specialty pharmaceutical company’s stock worth $1,178,000 after purchasing an additional 1,660 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Supernus Pharmaceuticals by 15.2% in the third quarter. BNP Paribas Financial Markets now owns 84,077 shares of the specialty pharmaceutical company’s stock valued at $2,622,000 after purchasing an additional 11,125 shares in the last quarter. Finally, FMR LLC increased its stake in Supernus Pharmaceuticals by 101.1% in the third quarter. FMR LLC now owns 16,903 shares of the specialty pharmaceutical company’s stock valued at $527,000 after purchasing an additional 8,499 shares during the last quarter.

Analyst Upgrades and Downgrades

SUPN has been the subject of several research analyst reports. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th.

Supernus Pharmaceuticals Price Performance

SUPN opened at $37.03 on Wednesday. The business has a 50 day simple moving average of $34.31 and a 200-day simple moving average of $31.41. The stock has a market capitalization of $2.04 billion, a P/E ratio of 34.61 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 12 month low of $25.53 and a 12 month high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The business had revenue of $175.70 million for the quarter, compared to analysts’ expectations of $157.35 million. During the same period in the prior year, the company posted ($0.29) EPS. The business’s revenue for the quarter was up 14.2% on a year-over-year basis. Research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 15,000 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total transaction of $554,700.00. Following the sale, the senior vice president now directly owns 8,200 shares in the company, valued at approximately $303,236. The trade was a 64.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Georges Gemayel sold 14,213 shares of the firm’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the completion of the transaction, the director now owns 13,315 shares of the company’s stock, valued at approximately $487,595.30. This represents a 51.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 154,213 shares of company stock valued at $5,660,180 in the last quarter. 9.30% of the stock is currently owned by corporate insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.